Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2010

View Archived Issues

HG-829 reverses resistance to antineoplastic agents in vitro and in vivo

ONO-013105 synergizes with rituximab in models of MCL and advances in phase I trial

New inhibitors claimed of PI3K-alpha and PI3K-gamma

Korean scientists divulge new amide compounds for treatment of bone disorders

Unigene and GSK amend licensing agreement and advance PTH program to phase II in osteoporosis

Phase I data support safety of BIIB-021 plus trastuzumab in HER2-positive breast cancer

MLN-0905 has antitumor effects in murine model of diffuse large B-cell lymphoma

Proton MRS can measure potential biomarkers for delirium in brain

MGN-1601 enters phase I/II study in advanced renal cancer

FDA grants Hemispherx an extension to modify its NDA for Ampligen

Rifadin capsules filed in Japan for nontuberculous mycobacterial disease

Orion identifies novel inhibitors of MT-SP1

GlaxoSmithKline claims new monoamine reuptake inhibitors

New modulators of metabotropic glutamate mGlu2 receptor discovered

Amarillo Biosciences completes enrollment in phase II trial of interferon alfa lozenges

Phase I safety data released on Immunovaccine's DPX-0907 cancer vaccine

Tesaro gains development rights to antiemetic rolapitant hydrochloride

Tolerx begins phase I TRX-518 trial for the treatment of cancer

FDA accepts for review sNDA for Definity in stress echocardiography

Phase IIa results reported for Creabilis' CT-327 in atopic dermatitis

Pharmasset begins exploratory trial of PSI-7977 in chronic hepatitis C

Vivus responds to FDA's complete response letter regarding Qnexa

Roflumilast approved in Canada for severe COPD in adults

Evolva begins multiple-ascending-dose phase I trial of EV-077

Kiacta enters phase III trial for prevention of renal decline in AA amyloidosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.